About Us
For Sponsors
For Researchers
Conditions
ADHD
ALS
Asthma
Autism
Eczema
IVF
MDS
Osteoarthritis
Psoriasis
Rheumatoid Arthritis
Treatments
Contrave
Dsuvia
Epidiolex
Ibrutinib
Kybella
Platelet-Rich Plasma
Testosterone
Xarelto
Xiidra
Yondelis
Cities
Anaheim, CA
Baltimore, MD
Boston, MA
Chicago, IL
High Point, NC
Houston, TX
Las Vegas, NV
Los Angeles, CA
Miami, FL
San Diego, CA
States
Colorado
Florida
Indiana
Maine
Massachusetts
Michigan
New York
Ohio
Pennsylvania
Texas
Myasthenia Gravis Clinical Trials 2022
Myasthenia Gravis studies recruiting patients for novel treatments. Filter by phase, distance, and inclusion criteria to find your perfect myasthenia gravis clinical trial in 2022.
Condition
Myasthenia Gravis
Location
Distance
10 Miles
Any
Age
Search
Clinical Trials
Myasthenia Gravis Clinical Trials 2022
Phase-Based Progress Estimates
2
Effectiveness
3
Safety
Batoclimab 340 Mg SC Bi-weekly
for Myasthenia Gravis, Generalized
Carlsbad, CA
18+
All Sexes
Phase 3
Recruiting
Class II
Carlsbad, CA
18+
All Sexes
The purpose of this 3-period study is to confirm the efficacy and safety of batoclimab in participants with gMG. In Period 1, participants will be randomized 1:1:1 to receive batoclimab 680 milligrams (mg) subcutaneously (SC) once a week (QW) or 340 mg SC QW or placebo. The primary efficacy endpoint will be assessed by change in the myasthenia gravis activities of daily living (MG- ADL) score in acetylcholine receptor antibody seropositive (AChRAb+) participants. In Period 2, participants previously treated with batoclimab will be re-randomized to stay on batoclimab (340 mg SC QW or 340 mg SC every two weeks) or receive placebo treatment. The secondary endpoint of maintenance of efficacy will be assessed by change in the MG- ADL score in AChRAb+ participants. Participants demonstrating a response to batoclimab during either Period 1 or 2 may enter the long-term extension (Period 3).
Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Nipocalimab
for Myasthenia Gravis
Aurora, CO
< 18
All Sexes
Phase 2 & 3
Recruiting
Class II
Aurora, CO
< 18
All Sexes
The purpose of this study is to determine the effect of nipocalimab on total serum immunoglobulin G (IgG) in pediatric participants 2 to less than (<) 18 years of age, the safety and tolerability of treatment with nipocalimab in children and adolescents and to evaluate the pharmacokinetics (PK) of nipocalimab in children and adolescents with generalized myasthenia gravis (gMG) who have an insufficient clinical response to ongoing, stable standard-of-care therapy.
Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Acupuncture
for Myasthenia Gravis
Saint Paul, MN
18+
All Sexes
Recruiting
Saint Paul, MN
18+
All Sexes
The purpose of the study is to determine the effect acupuncture treatment on individuals with a diagnosis of Myasthenia Gravis (MG). A total of 20 people with MG will be enrolled in this study to receive acupuncture treatment 2 times a week for 12 weeks. Participants will be randomized into two groups: 1) Immediate start and 2) Delayed start (12 weeks). The delayed start group will act as a control group for the first 12 weeks, but then receive acupuncture treatment for 12 weeks. It is hypothesized that patients with MG who receive acupuncture treatment will have improved quality of life and activities of daily living compared to no treatment.
Phase-Based Progress Estimates
1
Effectiveness
2
Safety
ALXN2050
for Myasthenia Gravis, Generalized
Houston, TX
18+
All Sexes
Phase 2
Recruiting
Class II
Houston, TX
18+
All Sexes
This study will evaluate the efficacy and safety of ALXN2050 (120 milligrams [mg], 180 mg) in participants with generalized myasthenia gravis (gMG). Safety will be monitored throughout the study.
Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Robotic-Assisted Surgery
for Myasthenia Gravis
Boston, MA
18+
All Sexes
Recruiting
Stage I
Boston, MA
18+
All Sexes
To confirm the safety and performance of the da Vinci SP Surgical System, Instruments and Accessories in pulmonary lobectomy, and in thymectomy procedures.
Phase-Based Progress Estimates
2
Effectiveness
3
Safety
Tolebrutininb
for Myasthenia Gravis
Washington, United States
18+
All Sexes
Phase 3
Waitlist Available
Class II
Washington, United States
18+
All Sexes
This is a multicenter, randomized, double blind, placebo-controlled, Phase 3 study to evaluate the efficacy and safety of tolebrutinib compared with placebo in adult participants aged 18 to 85 years old with moderate-to-severe gMG, who are receiving Standard of Care (SoC). The double-blind (DB) treatment period of 26 weeks will comprise of 7 site visits followed by a 2-year open label extension (OLE) period with quarterly visits. The efficacy of tolebrutinib versus placebo during DB period will be assessed by clinical evaluations, that include scales based on physician examination or direct participant feedback i.e., patient reported outcomes (PROs). These evaluations will continue during the OLE in order to measure long term efficacy and safety.
Phase-Based Progress Estimates
2
Effectiveness
3
Safety
Pozelimab (REGN3918) + Cemdisiran
for Myasthenia Gravis, Generalized
Naples, FL
18+
All Sexes
Phase 3
Recruiting
Class II
Naples, FL
18+
All Sexes
The primary objective is: To evaluate the effect of pozelimab + cemdisiran on daily functioning that is impacted by signs and symptoms in patients with symptomatic generalized myasthenia gravis (gMG) The secondary objectives of the study are: To evaluate the effect of pozelimab + cemdisiran (ie, combination) and cemdisiran monotherapy on: Clinician-assessed signs of myasthenia gravis (MG) and muscle strength Daily functioning that is impacted by signs and symptoms in patients with symptomatic gMG (cemdisiran monotherapy only). Proportion of patients with improvements in daily function that is impacted by signs and symptoms of MG Proportion of patients that have improvements in clinician-assessed signs of MG and muscle strength Health related quality of life Proportion of patients with minimal MG symptoms Patient- and clinician-reported signs and symptoms of MG To evaluate the safety and tolerability of pozelimab + cemdisiran and cemdisiran monotherapy To assess the concentration of total pozelimab in serum To assess the concentrations of cemdisiran and its metabolites in plasma To assess the immunogenicity of pozelimab To assess the concentration of total C5 in plasma To assess the immunogenicity of cemdisiran To study the effect of pozelimab + cemdisiran and cemdisiran monotherapy on complement activation
Phase-Based Progress Estimates
2
Effectiveness
3
Safety
Satralizumab
for Myasthenia Gravis, Generalized
Saint Louis, MO
Any Age
All Sexes
Phase 3
Recruiting
Class II
Saint Louis, MO
Any Age
All Sexes
This study is evaluating whether a drug called satralizumab can improve symptoms of myasthenia gravis.
Phase-Based Progress Estimates
2
Effectiveness
3
Safety
Nipocalimab
for Myasthenia Gravis
Saint Louis, MO
18+
All Sexes
Phase 3
Recruiting
Class II
Saint Louis, MO
18+
All Sexes
This study is evaluating whether a drug called nipocalimab can improve symptoms of myasthenia gravis.
Phase-Based Progress Estimates
2
Effectiveness
3
Safety
Efgartigimod PH20 SC
for Myasthenia Gravis, Generalized
Palo Alto, CA
18+
All Sexes
Phase 3
Waitlist Available
Palo Alto, CA
18+
All Sexes
The purpose of this study is to evaluate the long-term safety and tolerability of efgartigimod PH20 SC 1000 mg, and the clinical efficacy, PD, pharmacokinetics (PK), immunogenicity, impact on the quality of life (QoL) of the participants, treatment satisfaction, and administration method preference, and the feasibility of self- and caregiver-supported administration of the SC injection. Study details include: Study duration: 2 years Treatment duration: 3-week treatment periods, repeated as needed with at least 28 days in between treatment periods Health measurements: total levels of immunoglobulin G (IgG), Acetylcholine receptor binding autoantibodies (AChR-Ab) levels, Myasthenia Gravis Activities of Daly Living (MG-ADL).
Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Magnetic Levator Prosthesis (MLP)
for Stroke
Boston, MA
Any Age
All Sexes
Recruiting
Boston, MA
Any Age
All Sexes
This study is evaluating whether two non-surgical devices designed to improve eye lid opening for patients with severe Blepharoptosis (incomplete opening of the eyelids) are effective.
Phase-Based Progress Estimates
2
Effectiveness
3
Safety
Rozanolixizumab
for Myasthenia Gravis, Generalized
Houston, TX
18+
All Sexes
Phase 3
Waitlist Available
Houston, TX
18+
All Sexes
This study is evaluating whether a drug called rozanolixizumab is safe and effective for people with generalized myasthenia gravis.
Phase-Based Progress Estimates
2
Effectiveness
3
Safety
Inebilizumab
for Myasthenia Gravis
Burlington, VT
18+
All Sexes
Phase 3
Recruiting
Class II
Burlington, VT
18+
All Sexes
This study is evaluating whether a drug may help reduce the risk of developing Alzheimer's disease.
Phase-Based Progress Estimates
2
Effectiveness
3
Safety
Zilucoplan (RA101495)
for Myasthenia Gravis, Generalized
Chapel Hill, NC
18+
All Sexes
Phase 3
Waitlist Available
Chapel Hill, NC
18+
All Sexes
This study is evaluating whether zilucoplan is safe and effective for people with gMG.
Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Descartes-08
for Myasthenia Gravis, Generalized
Aurora, CO
18+
All Sexes
Phase 1 & 2
Recruiting
Aurora, CO
18+
All Sexes
This study is evaluating whether a type of white blood cell called CAR T-cells may help treat a disease called Generalized Myasthenia Gravis.
Phase-Based Progress Estimates
2
Effectiveness
3
Safety
Ravulizumab
for Myasthenia Gravis, Generalized
East Lansing, MI
18+
All Sexes
Phase 3
Waitlist Available
Class II
East Lansing, MI
18+
All Sexes
This study is evaluating whether a drug called ravulizumab can improve symptoms of generalized myasthenia gravis.
Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Magnetic Levator Prosthesis (MLP)
for Blepharoptosis
Boston, MA
Any Age
All Sexes
Waitlist Available
Boston, MA
Any Age
All Sexes
This study is evaluating whether a magnetic device can help improve eyelid movement for individuals with blepharoptosis.
Phase-Based Progress Estimates
2
Effectiveness
3
Safety
Eculizumab
for Myasthenia Gravis
Saint Louis, MO
< 18
All Sexes
Phase 3
Waitlist Available
Class II
Saint Louis, MO
< 18
All Sexes
This study is evaluating whether a medication may help treat a rare form of muscular dystrophy.
Phase-Based Progress Estimates
2
Effectiveness
3
Safety
Amifampridine Phosphate
for Myasthenia Gravis
Cleveland, OH
18+
All Sexes
Phase 3
Waitlist Available
Cleveland, OH
18+
All Sexes
This study is evaluating whether amifampridine phosphate is safe for people with MuSK-MG.
Phase-Based Progress Estimates
2
Effectiveness
3
Safety
Human Normal Immunoglobulin G (IgG)
for Myasthenia Gravis
Vancouver, Canada
18+
All Sexes
Phase 3
Recruiting
Class II
Vancouver, Canada
18+
All Sexes
This is a prospective open-label, uncontrolled, single-blind, pilot clinical trial. The primary objective is to assess the efficacy, safety, feasibility and tolerability of SCIG in patients with worsening MG. Participants with moderate worsening of MG symptoms (MGFA Class II and III) who are considered to be appropriate for immunoglobulin therapy will be screened for the study by the treating neurologist. Patients will be receive 2gm/kg (150gm for a 75kg patient) of 20% SCIG (Hizentra) infused over 4 weeks in a dose escalating manner. Additionally, this study will be assessing the feasibility of employing SCIG as an alternative therapy to IVIG in patients with MG exacerbation. The cost-effectiveness of SCIG versus IVIG will be evaluated, and the impact of SCIG therapy will be assessed from both a health-resource perspective and from a patient perspective.
Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)
for Myasthenia Gravis
Chicago, IL
18+
All Sexes
Phase < 1
Waitlist Available
Chicago, IL
18+
All Sexes
The purpose of this study is to determine whether the drug Leukine (GM-CFS) is safe and tolerated by patients with autoimmune myasthenia gravis (MG).
Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Autologous Hematopoietic Stem Cell Transplantation
for Stiff Person Syndrome
Seattle, WA
Any Age
All Sexes
Phase 2
Recruiting
Seattle, WA
Any Age
All Sexes
This study is evaluating whether a combination of chemotherapy and a stem cell transplant may help treat patients with autoimmune neurological disease.
Phase-Based Progress Estimates
2
Effectiveness
3
Safety
Efgartigimod Concentrate For Solution For Infusion 20 Mg/mL
for Myasthenia Gravis, Generalized
Philadelphia, PA
18+
All Sexes
Phase 3
Recruiting
Class II
Philadelphia, PA
18+
All Sexes
The purpose of this open-label study is to investigate the efficacy, safety, and tolerability of a continuous regimen of efgartigimod compared with a cyclic regimen in participants with Generalized Myasthenia Gravis (gMG). Study details include: The study duration will be up to 128 weeks (including screening) Part A (regimen comparison period) - 21 weeks Part B (extension period) - up to 105 weeks The visit frequency, including virtual visits, will be weekly through Week 21 and every 5 weeks for the remainder of the study.
Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Exercise
for Myasthenia Gravis
Baltimore, MD
18+
All Sexes
Phase 1
Waitlist Available
Baltimore, MD
18+
All Sexes
Generalized fatigue in myasthenia gravis results in physical deconditioning that reduces fitness and increases risk of obesity, hypertension, elevated cholesterol and type 2 diabetes. This study will examine how active and fit are 30 individuals with chronic, generalized myasthenic subjects. This study will also determine whether a 3 month home exercise program with aerobic, resistive, and pulmonary training can improve physical activity, strength, fitness, lung function and reduce cardiovascular disease risk.
1
Other Trials to Consider
Nipocalimab
for Myasthenia Gravis
Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Phase 2 & 3
Recruiting
Class II
Aurora, CO
< 18
All Sexes
PDC-1421 Capsule
for Psychosis, Involutional
Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Phase 1 & 2
Waitlist Available
Stage I
Los Angeles, CA
18+
All Sexes
Fludarabine + Total Marrow Irradiation
for Myelodysplastic Syndromes
Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Phase 1 & 2
Recruiting
High Risk
Indianapolis, IN
18+
All Sexes
ALXN2050
for Myasthenia Gravis, Generalized
Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Phase 2
Recruiting
Class II
Houston, TX
18+
All Sexes
Efgartigimod PH20 SC
for Myasthenia Gravis, Generalized
Phase-Based Progress Estimates
2
Effectiveness
3
Safety
Phase 3
Waitlist Available
Palo Alto, CA
18+
All Sexes
Ravulizumab
for Myasthenia Gravis, Generalized
Phase-Based Progress Estimates
2
Effectiveness
3
Safety
Phase 3
Waitlist Available
Class II
East Lansing, MI
18+
All Sexes
Nipocalimab
for Myasthenia Gravis
Phase-Based Progress Estimates
2
Effectiveness
3
Safety
Phase 3
Recruiting
Class II
Saint Louis, MO
18+
All Sexes
Pozelimab (REGN3918) + Cemdisiran
for Myasthenia Gravis, Generalized
Phase-Based Progress Estimates
2
Effectiveness
3
Safety
Phase 3
Recruiting
Class II
Naples, FL
18+
All Sexes
Satralizumab
for Myasthenia Gravis, Generalized
Phase-Based Progress Estimates
2
Effectiveness
3
Safety
Phase 3
Recruiting
Class II
Saint Louis, MO
Any Age
All Sexes
Biodesign Otologic Graft
for Tympanic Membrane Perforation
Phase-Based Progress Estimates
3
Effectiveness
3
Safety
Phase 4
Recruiting
Novi, MI
18+
All Sexes
Trauma-focused Treatment
for Post Traumatic Stress Disorder (PTSD)
Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Recruiting
Boston, MA
18+
All Sexes
Avoid Coffee
for Coffee
Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Recruiting
1 Prior Treatment
San Francisco, CA
18+
All Sexes
Behavioral Intervention
for Malignant Abdominal Neoplasm
Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Recruiting
Houston, TX
18+
All Sexes
ESupport Health Weekly Group Sessions For PwMS
for Multiple Sclerosis
Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Recruiting
New York, NY
18+
All Sexes
Popular Categories
Top 10 Oncology Clinical Trials
Oncology Clinical Trials 2022
Top 10 AML Clinical Trials
AML Clinical Trials 2022
Top 10 Hearing Loss Clinical Trials
Hearing Loss Clinical Trials 2022
Top 10 Cirrhosis Clinical Trials
Cirrhosis Clinical Trials 2022
Top 10 Follicular Lymphoma Clinical Trials
Follicular Lymphoma Clinical Trials 2022
Top 10 Cholesterol Clinical Trials
Cholesterol Clinical Trials 2022
Top 10 Avycaz Clinical Trials
Avycaz Clinical Trials
Top 10 Saxenda Clinical Trials
Saxenda Clinical Trials
Top 10 Latisse Clinical Trials
Latisse Clinical Trials
Top 10 Xofluza Clinical Trials
Xofluza Clinical Trials
Top 10 Prozac Clinical Trials
Prozac Clinical Trials
Top 10 Vioxx Clinical Trials
Vioxx Clinical Trials
Top 10 Liptruzet Clinical Trials
Liptruzet Clinical Trials
Top 10 Lovaza Clinical Trials
Lovaza Clinical Trials
Top 10 ALL Clinical Trials
ALL Clinical Trials 2022
Relevant Clinical Trials
Prostate Clinical Trials 2022
Sepsis Clinical Trials 2022
Uterine Fibroid Clinical Trials 2022
Essential Tremor Clinical Trials 2022
Gout Clinical Trials 2022
Actinic Keratosis Clinical Trials 2022
Borderline Personality Disorder Clinical Trials 2022
Spinal Muscular Atrophy Clinical Trials 2022
Diet Clinical Trials 2022
Breast Reduction Clinical Trials 2022
Yeast Infection Clinical Trials 2022
Marfan Syndrome Clinical Trials 2022
Flu Clinical Trials 2022
Dermatomyositis Clinical Trials 2022
Sibo Clinical Trials 2022
Gynecomastia Clinical Trials 2022
Osteogenesis Imperfecta Clinical Trials 2022
Cyclic Vomiting Syndrome Clinical Trials 2022
Lipedema Clinical Trials 2022
Acne Scar Clinical Trials 2022
Top Oncology Trials
Cancer Clinical Trials 2022
Pancreas Cancer Clinical Trials 2022
Prostate Cancer Clinical Trials 2022
Breast Cancer Clinical Trials 2022
Oncology Clinical Trials 2022
Pancreatic Cancer Clinical Trials 2022
Melanoma Clinical Trials 2022
Multiple Myeloma Clinical Trials 2022
Triple Negative Breast Cancer Clinical Trials 2022
Ovarian Cancer Clinical Trials 2022
Lung Cancer Clinical Trials 2022
Colon Cancer Clinical Trials 2022
CLL Clinical Trials 2022
Small Cell Lung Cancer Clinical Trials 2022
Esophageal Cancer Clinical Trials 2022
Mesothelioma Clinical Trials 2022
Leukemia Clinical Trials 2022
AML Clinical Trials 2022
Bladder Cancer Clinical Trials 2022
Cholangiocarcinoma Clinical Trials 2022
Popular Clinical Trials
COVID Clinical Trials 2022
Depression Clinical Trials 2022
ALS Clinical Trials 2022
Coronavirus Clinical Trials 2022
IVF Clinical Trials 2022
Marijuana Clinical Trials 2022
Type 1 Diabetes Clinical Trials 2022
Lupus Clinical Trials 2022
Tinnitus Clinical Trials 2022
PTSD Clinical Trials 2022
Diabetes Clinical Trials 2022
Rheumatoid Arthritis Clinical Trials 2022
Psoriasis Clinical Trials 2022
Multiple Sclerosis Clinical Trials 2022
Obesity Clinical Trials 2022
Psilocybin Clinical Trials 2022
Weight Loss Clinical Trials 2022
Osteoarthritis Clinical Trials 2022
Lyme Disease Clinical Trials 2022
Retinitis Pigmentosa Clinical Trials 2022
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
461 2nd St., San Francisco, CA
hello@withpower.com
(415) 900-4227
About Us
Join The Team!
Conditions
ADHD
ALS
Asthma
Autism
Eczema
IVF
MDS
Osteoarthritis
Psoriasis
Rheumatoid Arthritis
Locations
Colorado
Florida
Indiana
Maine
Massachusetts
Michigan
New York
Ohio
Pennsylvania
Texas
Cancer Related
Chronic Lymphocytic Leukemia
Esophageal
Leukemia
Lymphoma
Melanoma
Multiple Myeloma
Pancreatic Cancer
Prostate Cancer
Small Cell Lung Cancer
Triple Negative Breast Cancer
Treatments
Contrave
Dsuvia
Epidiolex
Ibrutinib
Kybella
Platelet-Rich Plasma
Testosterone
Xarelto
Xiidra
Yondelis
Cities
Anaheim, CA
Baltimore, MD
Boston, MA
Chicago, IL
High Point, NC
Houston, TX
Las Vegas, NV
Los Angeles, CA
Miami, FL
San Diego, CA
Terms of Service
Privacy Policy